In an overview of cost-effectiveness studies of prostate cancer screening, it was argued that the sensitivity, specificity and positive predictive value of the PSA test are acceptable (Crawford and Abrahamsson, 2008). The gene discussed is KLK3; the disease is prostate cancer.